Fresenius Medical Care Midwest Kenosha is a medicare approved dialysis facility center in Kenosha, Wisconsin and it has 13 dialysis stations. It is located in Kenosha county at 6804 Green Bay Rd, Kenosha, WI, 53142. You can reach out to the office of Fresenius Medical Care Midwest Kenosha at (262) 697-6323. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fresenius Medical Care Midwest Kenosha has the following ownership type - Profit. It was first certified by medicare in March, 2005. The medicare id for this facility is 522564 and it accepts patients under medicare ESRD program.
| Name | Fresenius Medical Care Midwest Kenosha |
|---|---|
| Location | 6804 Green Bay Rd, Kenosha, Wisconsin |
| No. of Dialysis Stations | 13 |
| Medicare ID | 522564 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 6804 Green Bay Rd, Kenosha, Wisconsin, 53142 | |
| (262) 697-6323 | |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
| NPI Number | 1174556856 |
| Organization Name | Midwest Kidney Care-kenosha Branch |
| Doing Business As | Midwest Kidney Care, Llc |
| Address | 6804 Green Bay Rd Kenosha, Wisconsin, 53142 |
| Phone Number | (262) 697-6323 |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 53% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 22% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 25% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 43% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 28% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 29% | 14% |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 45% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 30% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 25% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 40% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 39% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 12% |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 79% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 21% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 40% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 38% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 12% |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 30 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 13 |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 84 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 700 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fresenius Medical Care Midwest Kenosha with elevated calcium levels.
| Patients with hypercalcemia | 84 |
| Hypercalcemia patient months | 700 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 94 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 22 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 55 |
| Patient months included in arterial venous fistula and catheter summaries | 414 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 64 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 14 |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 61 |
| Hospitalization Rate in facility | 199.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 331.9 |
| Hospitalization Rate: Lower Confidence Limit | 124 |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Fresenius Medical Care Midwest Kenosha were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 27.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.1 |
| Readmission Rate: Lower Confidence Limit | 18.5 |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fresenius Medical Care Midwest Kenosha get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .42 (As Expected) |
| SIR: Upper Confidence Limit | 1.4 |
| SIR: Lower Confidence Limit | .07 |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fresenius Medical Care Midwest Kenosha's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 44 |
| Transfusion Rate in facility | 19.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 94.4 |
| Transfusion Rate: Lower Confidence Limit | 4.9 |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Fresenius Medical Care Midwest Kenosha lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 271 |
| Mortality Rate in facility | 19 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 26 |
| Mortality Rate: Lower Confidence Limit | 13.5 |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago
Fresenius Medical Care Midwest Kenosha Location: 6804 Green Bay Rd, Kenosha, Wisconsin, 53142 Phone: (262) 697-6323 |
Kidney Replacement Therapies Location: 6125 Green Bay Rd, Kenosha, Wisconsin, 53142 Phone: (262) 564-8636 |
News Archive
Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.
How can we improve the identification and prompt diagnosis of genetic diseases? A new Research Unit at Charité - Universitätsmedizin Berlin will set out to identify and reliably interpret important non-coding sections of our genomes in the hope of finding the diagnosis for unsolved diseases.
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
CAS Medical Systems, Inc. today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy.
› Verified 2 days ago